Center for Medical Ethics and Health Policy Staff Publications
Language
English
Publication Date
7-15-2024
Journal
AIDS
DOI
10.1097/QAD.0000000000003912
PMID
38932749
PMCID
PMC11212673
PubMedCentral® Posted Date
6-27-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.
Keywords
Humans, Benzoxazines, Cyclopropanes, Female, Alkynes, Breast Neoplasms, HIV Infections, Middle Aged, Adult, Anti-HIV Agents, Survival Analysis, Aged
Published Open-Access
yes
Recommended Citation
Johnson, Arthur T; Ntloedibe, Taolo; Mendez Reyes, Jose Euberto; et al., "Impact of Efavirenz on Hormone-Positive Breast Cancer Survival in Women Living With HIV" (2024). Center for Medical Ethics and Health Policy Staff Publications. 87.
https://digitalcommons.library.tmc.edu/med_ethics/87